Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab in fistulizing perianal Crohn's disease
ISRCTN15970897Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of guselkumab in Crohn's disease (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Percentage of participants who achieve combined fistula remission at week 24 and Combined fistula remission definition. Started Apr 2022; status: active, not recruiting.
02
Drugs
guselkumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on ISRCTN15970897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15970897.